Margaret Tisdale

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Margaret Tisdale (née Breeze; 10 September 1950[citation needed] – 29 April 2015) was a Welsh-born clinical virologist known for her studies of antiviral resistance in HIV and influenza virus, and for coordinating the development of the anti-influenza drug zanamivir.[1][2]

Biography[edit]

Born in Welshpool, Tisdale was educated at Trefnanney School and Welshpool Comprehensive, before attending Guildford University.[2]

Tisdale spent 33 years as a researcher at the Wellcome Research Laboratories, GlaxoWellcome and GlaxoSmithKline, where she eventually became head of clinical virology.[1][2] She was an expert in HIV drug resistance and in optimising antiretroviral therapy.[1] Tisdale headed the development of the influenza neuraminidase inhibitor zanamivir,[1] which Glaxo licensed from Biota in 1990. She established the global Neuraminidase Inhibitor Susceptibility Network in 1999 to track resistance to neuraminidase inhibitors in clinical strains of influenza virus.[1] She also published on antiviral drugs against rhinovirus, which causes the common cold.[3]

She died aged 64 in Wrestlingworth, Bedfordshire.[4]

Selected publications[edit]

References[edit]

  1. ^ a b c d e "Gone in 2015: Commemorating 10 Outstanding Women in Science". Scientific American Blog Network. Retrieved 2016-01-19.
  2. ^ a b c "Tributes paid to Montgomeryshire scientist Margaret Tisdale who has died, aged 64". Denbighshire Free Press. 2015-05-28. Retrieved 2016-01-19.
  3. ^ DJ Bauer; JWT Selway; JF Batchelor; M Tisdale; IC Caldwell; DAB Young (1981), "4′,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound", Nature, 292: 369–70, doi:10.1038/292369a0
  4. ^ Sarah Knapton (27 January 2016), "Antidepressants can raise the risk of suicide, biggest ever review finds", The Daily Telegraph, retrieved 31 January 2016